CASUS: Validation for Detection of Precursor Lesions (CASUS-WP4)
Developing a Complete Cervical Cancer Screening Solution Based on First-void Urine Self-sampling: Validation for Detection of Precursor Lesions
Sponsor: Amsterdam UMC, location VUmc
This NA trial investigates Cervical Cancer and Cervical Intraepithelial Neoplasia and is currently completed. Amsterdam UMC, location VUmc leads this study, which shows 8 recorded versions since 2020 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Sep 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jul 2022 — Jul 2024 [monthly]
Completed NA
Status: Recruiting → Completed
-
May 2022 — Jul 2022 [monthly]
Recruiting NA
▶ Show 3 earlier versions
-
Oct 2021 — May 2022 [monthly]
Recruiting NA
-
Jan 2021 — Oct 2021 [monthly]
Recruiting NA
-
Sep 2020 — Jan 2021 [monthly]
Recruiting NA
First recorded
Aug 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Amsterdam UMC, location VUmc
- Novosanis NV
- Self-screen B.V.
- Universiteit Antwerpen
For direct contact, visit the study record on ClinicalTrials.gov .